Investigators Link Novel Biomarker to Therapy in DLBCL Trial

Rachel Narozniak, MA
Published: Tuesday, Nov 12, 2019
Evan Ya-Wen Yu, MD, a professor in the Department of Medical Oncology, University of Washington School of Medicine, and clinical trials core director, Genitourinary Medical Oncology, Seattle Cancer Care Alliance

Owen O'Connor MD, PhD

Investigators are exploring the novel genetic biomarker Denovo Genomic Marker 1 (DGM1) as a potential predictor of benefit from the experimental agent enzastaurin in treatment-naïve patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common non-Hodgkin lymphoma subtype.1

Neither lenalidomide nor ibrutinib added to R-CHOP in either study extended survival: ROBUST did not meet its primary end point of progression-free survival, and PHOENIX missed its primary end point of event-free survival.4,5 However, positive trends with R2-CHOP were noted in subgroups with high-risk and advanced stage DLBCL.

Figure. Enzastaurin with R-CHOP in DGM1-Positive DLBCL

Figure. Enzastaurin with R-CHOP in DGM1-Positive DLBCL
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication